Search

 
 
 
Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

BIO ROUNDUP: 2019 TRIALS, PILGRIM PRICE CHAT, PRE-XMAS SALES & MORE

It's beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather....

15 For '19: Key Clinical Data to Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

On Monday, Xconomy began our annual look ahead at clinical trials that could define biotech and have profound healthcare effects in...

 
 
 
Imfinzi looks flimsy in AstraZeneca's Phase III head and neck cancer study

IMFINZI LOOKS FLIMSY IN ASTRAZENECA'S PHASE III HEAD AND NECK CANCER STUDY

Results of the Phase III EAGLE study leave Merck's Keytruda and Bristol's Opdivo as the dominant players in the space of HNSCC after...

 
 
 
Nobel Medicine Prize Honors Cancer Immunotherapy Pioneers Allison & Honjo

NOBEL MEDICINE PRIZE HONORS CANCER IMMUNOTHERAPY PIONEERS ALLISON & HONJO

[ Updated 11:45 am ET Oct. 1 with comments from press conference ] Harnessing the immune system to fight cancer has transformed the...

 
 
 
Bio Roundup: Alnylam's Moment, Read on Rebates, Skinny Plans & More

BIO ROUNDUP: ALNYLAM'S MOMENT, READ ON REBATES, SKINNY PLANS & MORE

Millions of people might be on vacation as we hit the dog days, but drug makers and politicians aren't taking a break from the gamesmanship...

Bio Roundup: An Alzheimer's Head-Scratcher, OUTBio, GSK & Gilead Shakeups  

BIO ROUNDUP: AN ALZHEIMER'S HEAD-SCRATCHER, OUTBIO, GSK & GILEAD SHAKEUPS  

The devil is in the details, and key clinical trial results made that abundantly clear this week. Eisai and partner Biogen released...

 
 
 

ONCOSEC PRESENTS UPDATE ON PISCES/KEYNOTE-695 PHASE 2B REGISTRATION-DIRECTED CLINICAL TRIAL IN COMBINATION WITH MERCK'S KEYTRUDA® FOR METASTATIC MELANOMA AT THE ASCO 2018 ANNUAL MEETING

SAN DIEGO, June 4, 2018 /PRNewswire/ - OncoSec Medical Incorporated , a company developing intratumoral cancer immunotherapies, today...

 
 
 
Merck Immunotherapy Drug Shines In Lung Cancer Study

MERCK IMMUNOTHERAPY DRUG SHINES IN LUNG CANCER STUDY

Research finds that more than two-thirds of lung cancer patients who received Keytruda plus chemotherapy would be alive a year later,...

 
 
 
New immunotherapy drug becomes first ever to DOUBLE survival in lung cancer patients

NEW IMMUNOTHERAPY DRUG BECOMES FIRST EVER TO DOUBLE SURVIVAL IN LUNG CANCER PATIENTS

Merck's Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone...

 
 
 

IMMUNOGEN STOCK CLIMBS ON POSITIVE OVARIAN CANCER DATA

ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination...

 
 
 
Roche Gains Ground on Rivals With Drug Combo's Success in Lung Cancer

ROCHE GAINS GROUND ON RIVALS WITH DRUG COMBO'S SUCCESS IN LUNG CANCER

Roche/Genentech reported this morning that its cancer immunotherapy drug, atezolizumab , has succeeded in a clinical study that could...